News

DNAtrix Collaborators Present Data on a Novel Oncolytic Adenovirus


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

DNAtrix Collaborators Present Data on a Novel Oncolytic Adenovirus Expressing OX40 Ligand that Promotes Antitumor Immunity
 

Date: 17/06/2015

DNAtrix, Inc., a leader in oncolytic virus therapy, has announced that Juan Fueyo, M.D., professor in the Department of Neuro-Oncology and Director of the Brain Tumor Program at The University of Texas MD Anderson Cancer Center presented results on a novel oncolytic adenovirus, Delta-24-RGDOX, that enhances antitumor immunity by expressing the immune checkpoint co-stimulator OX40 ligand (OX40L). The data were presented at the 9th International Conference on Oncolytic Virus Therapeutics this morning in Boston, MA. The OX40L virus technology has been licensed exclusively to DNAtrix by MD Anderson. OX40 is a member of the tumor necrosis factor receptor superfamily, and interactions between OX40 and OX40L act as costimulatory signals for T-cell activation. The augmentation of this interaction enhances antitumor immunity. The oncolytic OX40L technology combines a replication-competent oncolytic virus with a potent immune-modulator, which could provide a novel "one-two punch" in the fight against cancer.

For more click here
Source: First Word Pharma

© Catalyst Innovation Portal 2019